AACR 2022 | Clinical relevance of lipid biopsy and circulating tumor cells for precision medicine

Catherine Alix-Panabieres, PhD, University Medical Center of Montpellier, Montpellier, France, discusses the clinical relevance of the liquid biopsy test and circulating tumor cells (CTCs). Liquid biopsy is an important complementary tool to the tissue biopsy. For instance, the expression of a specific biomarker, such as PD-L1, in a tissue biopsy will complement the expression of the biomarker on CTCs. Furthermore, CTCs have predicted the clinical outcome of patients with breast cancer and non-small cell lung cancer. A benefit of the liquid biopsy test is that it can be easily repeated due to its non-invasive nature. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.